Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvectis Pharma (NVCT) Treasury Shares (2023 - 2026)

Nuvectis Pharma has reported Treasury Shares over the past 4 years, most recently at $2.9 million for Q1 2026.

  • Quarterly results put Treasury Shares at $2.9 million for Q1 2026, up 36.55% from a year ago — trailing twelve months through Mar 2026 was $2.9 million (up 36.55% YoY), and the annual figure for FY2025 was $2.2 million, up 63.03%.
  • Treasury Shares reached $2.9 million in Q1 2026 per NVCT's latest filing, up from $2.2 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $2.9 million in Q1 2026 and bottomed at $941496.0 in Q4 2023.
  • Median Treasury Shares over the past 4 years was $2.1 million (2025), compared with a mean of $1.9 million.
  • The largest annual shift saw Treasury Shares surged 63.03% in 2025 before it skyrocketed 36.55% in 2026.
  • Over 4 years, Treasury Shares stood at $941496.0 in 2023, then soared by 45.06% to $1.4 million in 2024, then soared by 63.03% to $2.2 million in 2025, then increased by 29.54% to $2.9 million in 2026.
  • Business Quant data shows Treasury Shares for NVCT at $2.9 million in Q1 2026, $2.2 million in Q4 2025, and $2.2 million in Q3 2025.